

**Supplementary Table 1 Additional patient demographics and baseline characteristics**

Quartile, anti-CCP2 concentration limits	CCP2 negative		Q1, 28–235		Q2, 236–609		Q3, 613–1046		Q4, 1060–4894	
	ABA (n=66)	ADA (n=54)	ABA (n=42)	ADA (n=55)	ABA (n=51)	ADA (n=46)	ABA (n=46)	ADA (n=51)	ABA (n=46)	ADA (n=51)
Weight, kg	82.1 (49.9, 126.3)	84.1 (57.6, 137.0)	80.2 (51.3, 120.7)	76.7 (41.0, 140.2)	73.6 (42.4, 156.5)	72.7 (50.7, 192.3)	81.6 (47.3, 144.2)	74.2 (45.5, 129.7)	74.4 (45.9, 140.0)	78.1 (46.4, 134.3)
Duration of disease category, %										
<6 months	27.3	16.7	11.9	16.4	19.6	26.1	10.9	13.7	15.2	21.6
≥6 months	72.7	83.3	88.1	83.6	80.4	73.9	89.1	86.3	84.8	78.4
Tender joint count	27.5 (0.0, 64.0)	29.0 (2.0, 67.0)	17.0 (2.0, 67.0)	21.0 (2.0, 68.0)	24.0 (6.0, 65.0)	24.5 (0.0, 64.0)	19.5 (1.0, 62.0)	25.0 (3.0, 64.0)	21.0 (5.0, 51.0)	23.0 (0.0, 64.0)
Swollen joint count	12.5 (0.0, 52.0)	12.0 (3.0, 48.0)	11.5 (4.0, 55.0)	15.0 (0.0, 47.0)	15.0 (2.0, 48.0)	12.0 (0.0, 55.0)	13.0 (0.0, 57.0)	13.0 (4.0, 49.0)	15.0 (0.0, 38.0)	15.0 (0.0, 34.0)
Subject pain assessment, VAS 100 mm	69.0 (12.0, 95.0)	69.0 (4.0, 98.0)	69.0 (22.0, 92.0)	68.3 (15.0, 97.0)	74.0 (7.0, 95.0)	63.0 (11.0, 99.0)	61.0 (14.0, 97.0)	76.0 (0.0, 99.0)	67.0 (6.0, 100.0)	63.0 (6.0, 98.0)
Subject global assessment, VAS 100 mm	60.0 (9.0, 98.0)	63.5 (6.0, 97.0)	60.0 (11.0, 91.0)	67.0 (11.0, 98.0)	71.0 (1.0, 100.0)	62.0 (11.0, 97.0)	60.0 (3.0, 91.0)	63.0 (0.0, 98.0)	68.5 (7.0, 100.0)	60.0 (3.0, 99.0)
Physician global assessment, VAS 100 mm	61.5 (10.0, 95.0)	60.5 (6.0, 94.0)	58.5 (27.0, 91.0)	57.0 (31.0, 96.0)	62.0 (13.0, 97.0)	65.0 (14.0, 95.0)	60.0 (12.0, 95.0)	60.0 (19.0, 88.0)	55.0 (20.0, 91.0)	63.0 (0.0, 100.0)
DAS28 (CRP) by category, %										
<3.2	6.1	3.7	2.4	1.8	0	4.3	2.2	0	2.2	3.9
3.2–5.1	34.8	33.3	50.0	32.7	31.4	23.9	28.3	31.4	26.1	31.4
>5.1	59.1	63.0	47.6	65.5	68.6	71.7	69.6	68.6	71.7	64.7
Joint space narrowing score	1.3 (0.0, 51.5)	2.0 (0.0, 56.5)	2.0 (0.0, 83.0)	4.0 (0.0, 68.0)	4.5 (0.0, 111.5)	2.0 (0.0, 115.0)	1.5 (0.0, 46.0)	2.3 (0.0, 70.5)	3.0 (0.0, 73.5)	2.0 (0.0, 48.0)

Erosion score	2.0 (0.0, 35.0)	3.8 (0.0, 58.0)	3.5 (0.0, 149.5)	5.8 (0.0, 75.0)	10.3 (0.0, 121.5)	5.5 (0.0, 123.0)	5.5 (0.0, 58.0)	4.8 (0.0, 73.5)	4.0 (0.0, 88.0)	5.0 (0.0, 59.5)
Estimated annual TSS progression	3.6 (0.0, 365.0)	4.6 (0.0, 93.8)	5.0 (0.0, 51.7)	6.6 (0.0, 228.8)	8.9 (0.0, 567.5)	6.0 (0.0, 275.0)	4.0 (0.0, 130.0)	6.0 (0.0, 176.7)	4.5 (0.0, 420.0)	5.0 (0.0, 57.5)

Data are expressed as median (min, max), unless otherwise stated.

ABA, abatacept; ADA, adalimumab; CCP2, cyclic citrullinated peptide-2; CRP, C-reactive protein; DAS28, Disease Activity Score 28; Q, quartile; TSS, total Sharp score; VAS, visual analogue scale.